Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma - Top-Institutions - MDSpire

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

  • By

  • Zijuan Liu

  • Yating Yan

  • Caihong Jiang

  • June 16, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Lille
    University of Lille

    Lille, Hauts-de-France

    Key Differentiators

    • Oncology

  • #2

    CHU Lille
    CHU Lille

    Lille, Hauts-de-France

    Key Differentiators

    • Oncology

  • #3

    INSERM U1189 OncoThAI
    INSERM U1189 OncoThAI

    Lille, Hauts-de-France

    Key Differentiators

    • Oncology

  • #4

    ONCOLille
    ONCOLille

    Lille, Hauts-de-France

    Key Differentiators

    • Oncology

Original Source(s)

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

  • by Zijuan Liu, Yating Yan, Caihong Jiang

  • June 16, 2026

Related Content

Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification

Correction: miR-17: from developmental regulatory hub to molecular engine driving tumourigenesis

Parabilis Sets Biotech IPO Record

The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement

  • June 15, 2026

  • 2 min